NUVL
Price
$68.19
Change
-$7.24 (-9.60%)
Updated
May 6, 04:59 PM (EDT)
Capitalization
5.42B
2 days until earnings call
SPRO
Price
$0.59
Change
-$0.02 (-3.28%)
Updated
May 6, 04:58 PM (EDT)
Capitalization
34.1M
3 days until earnings call
Ad is loading...

NUVL vs SPRO

Header iconNUVL vs SPRO Comparison
Open Charts NUVL vs SPROBanner chart's image
Nuvalent
Price$68.19
Change-$7.24 (-9.60%)
Volume$9.78K
Capitalization5.42B
Spero Therapeutics
Price$0.59
Change-$0.02 (-3.28%)
Volume$300
Capitalization34.1M
NUVL vs SPRO Comparison Chart
Loading...
NUVL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SPRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NUVL vs. SPRO commentary
May 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NUVL is a Hold and SPRO is a Hold.

Ad is loading...
COMPARISON
Comparison
May 06, 2025
Stock price -- (NUVL: $75.43 vs. SPRO: $0.61)
Brand notoriety: NUVL and SPRO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NUVL: 42% vs. SPRO: 76%
Market capitalization -- NUVL: $5.42B vs. SPRO: $34.1M
NUVL [@Biotechnology] is valued at $5.42B. SPRO’s [@Biotechnology] market capitalization is $34.1M. The market cap for tickers in the [@Biotechnology] industry ranges from $306.3B to $0. The average market capitalization across the [@Biotechnology] industry is $2.29B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NUVL’s FA Score shows that 0 FA rating(s) are green whileSPRO’s FA Score has 1 green FA rating(s).

  • NUVL’s FA Score: 0 green, 5 red.
  • SPRO’s FA Score: 1 green, 4 red.
According to our system of comparison, SPRO is a better buy in the long-term than NUVL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NUVL’s TA Score shows that 7 TA indicator(s) are bullish while SPRO’s TA Score has 4 bullish TA indicator(s).

  • NUVL’s TA Score: 7 bullish, 2 bearish.
  • SPRO’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, NUVL is a better buy in the short-term than SPRO.

Price Growth

NUVL (@Biotechnology) experienced а +0.31% price change this week, while SPRO (@Biotechnology) price change was -14.08% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.41%. For the same industry, the average monthly price growth was +12.48%, and the average quarterly price growth was -11.82%.

Reported Earning Dates

NUVL is expected to report earnings on Aug 07, 2025.

SPRO is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+0.41% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NUVL($5.42B) has a higher market cap than SPRO($34.1M). NUVL YTD gains are higher at: -3.641 vs. SPRO (-40.777). SPRO has higher annual earnings (EBITDA): -2.45M vs. NUVL (-280.37M). NUVL has more cash in the bank: 1.12B vs. SPRO (76.3M). SPRO has higher revenues than NUVL: SPRO (89.9M) vs NUVL (0).
NUVLSPRONUVL / SPRO
Capitalization5.42B34.1M15,883%
EBITDA-280.37M-2.45M11,458%
Gain YTD-3.641-40.7779%
P/E RatioN/A10.75-
Revenue089.9M-
Total Cash1.12B76.3M1,465%
Total DebtN/A4.62M-
FUNDAMENTALS RATINGS
SPRO: Fundamental Ratings
SPRO
OUTLOOK RATING
1..100
71
VALUATION
overvalued / fair valued / undervalued
1..100
46
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
66
PRICE GROWTH RATING
1..100
89
P/E GROWTH RATING
1..100
5
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
NUVLSPRO
RSI
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
72%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
77%
Momentum
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
89%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 7 days ago
81%
Bullish Trend 22 days ago
72%
Declines
ODDS (%)
Bearish Trend 29 days ago
79%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
N/A
N/A
View a ticker or compare two or three
Ad is loading...
NUVL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SPRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
NBCC25.300.36
+1.42%
Neuberger Berman Nxt Gen Cnnctd Cnsm ETF
GII64.910.04
+0.06%
SPDR® S&P® Global Infrastructure ETF
PAB41.83-0.09
-0.21%
PGIM Active Aggregate Bond ETF
OVL43.58-0.40
-0.91%
Overlay Shares Large Cap Equity ETF
BITX44.11-2.64
-5.65%
2x Bitcoin Strategy ETF

NUVL and

Correlation & Price change

A.I.dvisor indicates that over the last year, NUVL has been loosely correlated with ABCZF. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if NUVL jumps, then ABCZF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NUVL
1D Price
Change %
NUVL100%
-2.62%
ABCZF - NUVL
51%
Loosely correlated
N/A
ROIV - NUVL
46%
Loosely correlated
+0.78%
KYMR - NUVL
46%
Loosely correlated
-4.82%
RVMD - NUVL
44%
Loosely correlated
-2.27%
CRNX - NUVL
44%
Loosely correlated
-0.33%
More

SPRO and

Correlation & Price change

A.I.dvisor indicates that over the last year, SPRO has been loosely correlated with RCKT. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if SPRO jumps, then RCKT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SPRO
1D Price
Change %
SPRO100%
-5.72%
RCKT - SPRO
34%
Loosely correlated
-2.00%
KYMR - SPRO
34%
Loosely correlated
-4.82%
XENE - SPRO
34%
Loosely correlated
-1.93%
MGTX - SPRO
34%
Loosely correlated
-11.03%
TECH - SPRO
33%
Loosely correlated
-1.37%
More